Interrogating molecular data for medulloblastoma risk stratification

Affiliations

¹ Department of Experimental Medicine, Sapienza University of Rome, Rome 00161, Italy; IRCCS Neuromed Mediterranean Neurological Institute, Pozzilli, Italy. Electronic address: elisabetta.ferretti@uniroma1.it.
² Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy.

Free article

Comment

Elisabetta Ferretti et al. Lancet Oncol. 2018 Dec.

Free article

. 2018 Dec;19(12):1548-1549.

doi: 10.1016/S1470-2045(18)30585-0. Epub 2018 Nov 1.

¹ Department of Experimental Medicine, Sapienza University of Rome, Rome 00161, Italy; IRCCS Neuromed Mediterranean Neurological Institute, Pozzilli, Italy. Electronic address: elisabetta.ferretti@uniroma1.it.
² Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy.

No abstract available

Comment on

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC. Goschzik T, et al. Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1. Epub 2018 Nov 1. Lancet Oncol. 2018. PMID: 30392813 Free PMC article.